HOME >> BIOLOGY >> NEWS
UW-Madison research part of international mercury conference

a team that found that methylmercury levels in the watershed of the Tahquamenon River were elevated during periods when most of the water was coming from groundwater, not surface runoff.

The findings of this research suggest that the methylation process occurs amidst the rocks and gravel at the bottom of streams and in the sandy landscape that underlies coniferous forests in the Upper Peninsula. However, these findings are not specific to just Lake Superior and the Upper Peninsula: they confirm the importance of groundwater as a source of methylmercury to watersheds around the Great Lakes.

CONTACT: James Hurley, (608) 262-1136, hurley@aqua.wisc.edu

Bioavailability of Mercury in the Great Lakes Basin:
Thursday, Aug. 10, 10 a.m., Grand Terrace: Many fish in the Great Lakes Basin are contaminated by the most toxic form of mercury - methylmercury - and government health agencies issue fish consumption advisories to limit public exposure to this contaminant. The concentration of methylmercury in fish is not necessarily connected to the concentration of mercury in their immediate surroundings. Much of the methylmercury that enters Lake Michigan from tributary rivers appears to come from watersheds with large wetlands, not heavily industrialized regions. In addition, the mercury that contaminates sediments in waters around one industrial area - the city of Green Bay, Wis. - appears to be bound to the sediments in a way that keeps it from undergoing processes that otherwise would transform it into a more toxic form.

The transformation of mercury into methylmercury is caused by bacteria, and this process has been documented in wetlands and in sediments of lakes. This natural process appears to be creating more methylmercury in wetlands around Lake Michigan than in heavily industrialized areas. The situation in the waters around Green Bay, Wis., might be unique to th
'"/>

Contact: Kathleen Schmitt
media@mercury2006.org
608-262-6393
University of Wisconsin-Madison
3-Aug-2006


Page: 1 2 3 4 5

Related biology news :

1. UW-Madison work on stem cells, cardiac health to be presented at ACS
2. UW-Madison researchers find new way to sweeten key drugs
3. UW-Madison engineers squeeze secrets from proteins
4. UW-Madison small-scale research receives big boost
5. $3.4 million directed to key UW-Madison MS study
6. UW-Madison scientists zero in on drugs sweet spots
7. UW-Madison gains two new stem cell programs
8. Water research initiatives at UW-Madison
9. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
10. Saudi Arabias KAUST names WHOI first research partner
11. Multinational research: protecting ecology means understanding people, too

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Madison research part international mercury conference

(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: